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Abstarct. Recent studies confirm the need to find means to correct ischemic / reperfusion injury due to 
the hemodynamic medicine, which are already known do not have the proper cardioprotective effects. 
Key issue is the possibility of drug effects on the mitochondria of cardiomyocytes that controls the 
aerobic metabolism and maintenance of ATP admission into cardiomyocytes. Moreover mitochondria 
are the target of ischemia / reperfusion injury and involved in the cardioprotective mechanism ischemia 
and pharmacologic pre- and postconditioning. Effect of nitric oxide during ischemic reperfusion directed 
to mitochondria, is considered as the ultimate goal of cardioprotection. Preconditioning effects is begun 
from sarcolemmal membrane and then is directed to the cytoplasm through a plurality of stages of 
enzymes, including nitric oxide synthase (NOS), soluble guanylatecyclase (sGC) and protein kinase G 
(PKG). Thus, the signal is transmitted to the mitochondria, where it occurs cardioprotection. It is proved 
that the mitochondria provides protection of the heart against ischemia-reperfusion injury by opening the 
mitochondrial ATP-sensitive K + channels and by converting the capacity of mitochondria. Metabolic 
modulation concept can be used in the development of strategies cardioprotection for treatment in 
ischemic / reperfusion myocardial injury. 
Keywords: meldonium, pharmacological preconditioning, ischemic / reperfusion injury, heart. 
A brief review on the mechanisms of meldonium 
action. 
1. Influence on metabolic rate
Over the last few decades in medicine 
"metabolic" trend has been developing intensively, 
which aims at the analysis of cell metabolism 
disorders in cardiovascular disease. Changes in 
metabolism in ischemic cardiomyocytes can be 
regarded as the point of application of medical 
effects, particularly with drugs that can affect the 
processes occurring in mitochondria directly. By 
now, it has been created a number of drugs that 
directly affect the metabolic processes in 
cardiomyocytes, which is known as "myocardial 
cytoprotectors"  [1, 2, 3, 4, 5, 6]. 
It is accumulated activated long-chain fatty acids 
in myocardial cells in ischemic heart disease [7, 8]. 
These conjugates of fatty acids inhibit additional 
myocardial oxygenation and intracellular production 
of ATP. As it has been shown in some studies, the 
delay of synthesis of ATP as well as the intracellular 
accumulation of long-chain fatty acids can reduce L-
carnitine [9, 10]. In his studies on isolated porcine 
heart A. J. Liedtkeet al. [11] showed that carnitine 
blocked toxicity of long-chain fatty acids during 
hypoxic myocardial injury [12, 13]. 
However, under normal physiological 
concentration carnitine stimulates the transport of 
fatty acids. However, at high concentrations of 
carnitine it is pumping oxidized fatty acids from 
cells, which lead to the destruction of the 
myocardium. The ability to reduce the size of infarct 
is caused by a decrease of L-carnitine content in the 
tissues of the heart, and the subsequent inhibition of 
fatty acid transport and protection of the outer 
mitochondrial membrane of myocardial mitochondria 
Meldonium is a drug, which can reduce the level 
of carnitine. It blocks the synthesis of carnitine from 
γ-buterobetaine by reversible competitive inhibition 
of the enzyme gamma-butyrobetaine hydroxylase, 
which reduces the carnitine-dependent transport of 
fatty acids into the mitochondria [14, 15, 16]. 
Under normal conditions, when there is no 
shortage of oxygen, energy of the myocardium is 
mainly formed from fatty acids (FA) and glucose to 
adenosine triphosphate(ATP).According to the needs, 
it is occurred the mobilization of FA by the signal the 
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transport of FA across the mitochondrial membrane, 
where is supplied a sufficient amount of oxygen [17]. 
The result of mitochondrial β-oxidation of FA is 
formed acetyl-coenzyme A, which enters into the 
Krebs cycle, where ATP is synthesized. Another 
source of energy is a way of aerobic or anaerobic 
oxidation of glucose. However, myocardial 
metabolism varies in ischemic conditions. Short-
chain and long-chain FA enter the mitochondria, but 
there is not enough oxygen for the oxidation in the 
cell. Consequently, in the mitochondria of ischemic 
tissue it is accumulated metabolites unoxidized FA 
(acylcarnitine and acyl-coenzyme A (acyl-CoA)), 
which block transport earlier synthesi zed ATP from 
mitochondria into the cytosol. It causes a devastating 
effect on the cell membranes, which can lead cells to 
ischemic death. In addition, the accumulation of FA 
blocks the oxidation of glucose (it is studied during 
reperfusion of ischemic myocardium), and long-chain 
acylcarnitine contributes to reductions in ischemic 
myocardium, which leads to a vicious circle [6, 18]. 
The consequence of the toxic effect of non-oxidized 
metabolites FA is the blockade of  Ca 2+ -ATPase of 
the sarcoplasmic reticulum – calcium pump required 
for normal myocardial contractility. Consequently, it 
is necessary to restrict the flow of long-FA through 
the mitochondrial membrane for the correction of 
disturbed metabolism in the ischemic cells, 
simultaneously activate an alternative oxidation 
mechanism of the glucose for energy production in 
the cells [19, 20, 21]. In conditions of an oxygen 
shortage, it is more advantageous to use an oxidation 
of glucose than FA, since this process requires less 
amount oxygen by the cells. The formation of ATP 
through aerobic glycolysis requires 12% less oxygen 
than ATP production by the oxidation of FA.  
On the one hand, due to oxygen deficiency, the 
oxidized products of FA (acylcarnitine and acyl-CoA) 
accumulate in the myocardial ischemia, transport of 
ATP from mitochondria is blocked, cell membranes are 
destroyed, ionic composition is changed, and 
contracture of ischemic myocardium is developed. 
On the other hand, in hypoxia, glucose oxidation 
only occurs to lactate, acidosis and electrical instability 
of myocardium are developed, and arrhythmias arise. 
Thus, under ischemic conditions, it is essential to 
change the process of ATP production from FA 
oxidation to glycolysis. Thereby the need of the cells in 
oxygen for ATP production is reduced and it is 
prevented the accumulation of activated forms FA in 
the cells mitochondria  [22, 23]. Thus, it is important to 
use the oxygen sparing cytoprotection for the treatment 
of ischemic heart disease what are partial inhibitors of 
oxidation, activators of FA transport and glucose 
oxidation. All the preparations for metabolic therapy in 
cardiology can be divided into two groups: metabolic 
therapy preparations and preparations for the correction 
of metabolism. According to modern concepts, "ideal" 
metabolism corrector should prevent the accumulation 
of a large amount of unoxidized FA in the cells 
(prevention of cell membrane damage), activate the 
capture and oxidation of glucose by cells, inhibit the 
formation of lactate and stimulate the oxidation of 
pyruvate, as well as being able to prevent the formation 
of activated oxygen species (prevention oxidative 
stress). To the greatest degree, the "ideal" metabolism 
corrector may include well-known meldonium, because 
it affects all three components [24, 25, 26]. 
Cytoprotection mechanism of myocardial 
ischemia 
Meldonium belongs to a group of so-called 
cytoprotectors–antihypoxants, which provide protection 
and power of the body cells in conditions of ischemia 
and increased load. Mildronat is a structural analogue of 
the gamma-butyrobetaine (GBB), and therefore it is a 
competitive inhibitor of the GBB-hydroxylase – the last 
enzyme in the chain of carnitine biosynthesis in the 
body of humans and animals. Consequently, the drug 
decreases concentration of carnitine in serum, and in the 
cytosol, and mitochondrial matrixreversibly. By several 
researchers it has been proposed another possible way 
of meldonium influence on the content of carnitine in 
the body. It has been proved, that meldonium is also an 
inhibitor of carnitine reabsorption in the kidney, 
because it reduces renal transport of carnitine [27]. This 
mechanism provides a rapid decrease concentration of 
carnitinein the blood, which subsequently affects the 
gradual decrease of its concentration in the tissues. As a 
result, carnitine is not reabsorbed in the kidneys and is 
not metabolized again and excreted from the body 
immediately. Reduced carnitine levels has a dual effect 
on the human body. Limiting the availability of 
carnitine in the cytosol reduces the rate of activation 
and transport of long-chain FA to the place of their 
oxidation in mitochondria. In other words, in ischemia 
meldonium slows the rate of penetration and 
accumulation of long-chain fatty acids in mitochondria. 
Thereby it prevents blockage transport ATP from 
mitochondria to the cytosol and mitochondrial 
membrane integrity disruption due to the destroying 
properties of activated FA (acylcarnitine and acyl-
CoA).Due to the limited transport and oxidation of fatty 
acids in the mitochondria, their concentration in the 
cytosol increases, which is a signal of inclusion of 
alternative ways of energy production by aerobic 
glycolysis. It established, that meldonium increases the 
sensitivity of the insulin receptor to insulin and 
stimulate the insulin controlled glucose uptake that 
promotes the availability of glucose for inclusion in the 
energy production processes [28, 29]. 
At the same time meldonium activates the two 
most important enzyme of aerobic glycolysis – 
hexokinase and pyruvate dehydrogenase, which 
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involve pyruvate formed from sugars into the Krebs 
cycle, and it prevents the formation of lactate. 
Moreover, it is not only increased the activity of 
these enzymes under the influence of meldonium, as 
well as it is induced their biosynthesis. 
It is found, that the development of atherosclerosis 
and associated incidents of myocardial infarction, stroke 
and mortality directly correlated with the concentration 
of carnitine in the plasma of patients and increased 
levels trimethylamine oxide, which is a metabolite of 
carnitine because of its degradation by intestinal 
microorganisms [30, 31]. The explanation is that 
trimethylamine oxide, which is generated from 
carnitine, blocks macrophages capture of excessive 
amounts of cholesterol at its peak concentration in the 
blood, and return transport of cholesterol from plasma 
into the liver and the bile. As a result, the formation of 
cholesterol lesions can occur even at low levels of 
average values in plasma cholesterol concentration. 
This explains the mechanism by which meldonium 
significantly reduces plaque formation in the aorta in 
animals predisposed to atherosclerosis [32, 33]. Also, in 
patients with diabetes mellitus type 2 (DM2) of disease 
severity is directly correlated with the concentration of 
carnitine in the blood plasma [34]. This indicates the 
need to review the use of carnitine or carnitine-
containing products, as the degradation of carnitine to 
trimethylamine oxide significantly increased risk of 
atherosclerotic cardiovascular disease [30]. 
The only remedy in the world, which reduces the 
level of carnitine in humans, is meldonium. A pilot 
study in healthy volunteers, who received dietary 
trimethylamine, or its predecessors, has shown, that 
meldonium not only reduces the level of carnitine, but 
also reduces the level of formation of pro-atherogenic 
factor – trimethylamine oxide. Thus, the use of 
meldoniumto reduce to safe levels of carnitine and 
trimethylamine oxide is pathogenetically justified and 
purposeful way of preventing the development of 
atherosclerosis, and possibly the DM2.Consequently, 
meldonium is not only has unique cytoprotective 
properties in ischemic lesions of different etiology and 
localization, but also acts on the molecular mechanisms 
of atherosclerosis. Possible mechanisms of actions of 
meldonium is discussed in the publications of several 
authors [35, 36]. 
The points of action meldonium: protection of 
endothelial cells and cardioprotective effect 
Another important pathogenetic part of the 
defeat of the cardiovascular system is the 
development of dysfunction of vascular endothelium 
[37, 38, 39, 40], the consequent remodeling of the 
vascular wall and formation of angiopathy in arterial 
hypertension, which creates conditions for stable 
high blood pressure, reducing the effectiveness of 
antihypertensive drugs, the development of 
atherosclerotic lesions of arteries [41, 42, 43, 44]. 
A special role in the regulation of vascular tone 
plays nitric oxide. Nitric oxide is the most potent 
endogenous vasodilator. Nitricoxide, acting via 
guanylate cyclase, increases the formation of cyclic 
guanidin monophosphate, accumulation of which is the 
causes of vascular relaxation. Oxidative stress and the 
high concentration of free radicals leads to accelerated 
degradation of nitric oxide [45]. The development of 
endothelial dysfunction in hypertension accompanied 
by apoptosis of vascular endothelial cells caused by free 
radicals and a violation of the processes of intracellular 
energy transfer, so the correction of free-radical 
processes and intracellular metabolism in the vascular 
endothelium is one of the conditions for the effective 
treatment of hypertension and endothelial dysfunction. 
In this regard, meldonium may be the drug for 
correction dysfunction of the vascular endothelium and 
inhibition of free radical oxidation processes, as plasma 
concentration of carnitinsprecursor – gamma-
butyrobetaineincreasesunder the influence of 
meldonium, which is first and foremost – its esters – 
promotes NO biosynthesis – nitric oxide, which is the 
main factor regulating vascular tone, and also affects 
platelet aggregation and flexibility of red blood cells. It 
has shown that the γ-butyrobetaine esters have potent 
acetylcholine-like effect on blood vessel 
tonusMeldoniumhas the same effect [46, 47, 48]. 
Consequently, there are carnitine-independent effects of 
meldonium that cause a positive effect on the 
microcirculation. It should be emphasized, that the 
characteristic feature of NO is the ability rapidly (in less 
than 5 seconds) to diffuse through the membrane in its 
cells synthesize extracellular space and easily (without 
the receptors) to penetrate into the target cells. Inside 
the cell, it activates one and inhibits other enzymes 
participating in the regulation of cellular functions, and 
in fact acting as a local signaling molecule.NO is a 
potent vasodilator, which is synthesized in the 
endothelium of the vascular wall, it quickly penetrates 
into the subendothelial space, and affects vascular 
smooth muscle cells.NO molecule reduces intracellular 
calcium by adenylate cyclase mechanism. This leads to 
the relaxation of vascular smooth muscle cells, improve 
microcirculation and endothelial function [49, 50, 51]. 
New concepts in implementation of 
cardioprotective effects meldonium 
Another promising direction of studying the 
mechanisms of action meldonium is a 
pharmacological preconditioning. One version is the 
inclusion of compensatory mechanisms by inhibiting 
the synthesis of carnitine. 
In addition, a number of authors attempted to 
explore a new approach to the possible mechanism of 
action meldonium [52, 53, 54, 55]. In a number of 
experimental studies have been proven the ability 
meldonium activate a cascade of reactions through 
ATP-dependent potassium channel system which 
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lead to the implementation of the preconditioning 
phenomenon. Thus, they provide endotelio- and 
cardioprotective effect as well as anti-ischemic effect 
through this mechanism. These properties are 
essential for highly efficient drug, which is used for 
treatment and prevention of diseases associated with 
endothelial dysfunction Figure 1.
Figure 1. The hypothetical role meldonium in the mechanism of ischemic preconditioning. 
Note.К+ АТФканалы – ATP-dependent potassium channel; eNOS – endothelial NO-synthase; iNOS – inducible NO-synthase; 
L-NAME – N- nitro-L-arginine-methyl ester; NO – Nitric oxide; РФК – reactive oxygen species; ЦОГ-2 – cyclooxygenase-2 
ATP-dependent potassium channels are the 
effector mechanism in the implementation of anti-
ischemic effect, acts as a distant ischemic 
preconditioning and meldonium/ Nitric oxide acts as 
a trigger of ischemic preconditioning [56, 57, 58]. 
In either case, its synthesis is carried out by 
activation of the inducible and endothelial NO-
synthase. Meldonium competing for the receptors, 
gamma-butyrobetaine, it reduces the concentration 
of carnitine. Due to the geomitric similarity gamma-
butyrobetaine to acetylcholine it activates 
endothelial acetylcholine receptors which lead to the 
induction of NO synthesis. It follows that the 
meldonium can be recommended as the drug for 
pharmacological preconditioning. 
Thus, the therapeutic mechanism and protective 
action of meldonium is its effect on carnitine levels, 
trimethylamine oxide and metabolic energy pathways , 
which provides a more economical and efficient 
functioning of cells under conditions of oxygen 
shortage. Antiischemic effects of meldonium are 
achieved by reducing the intensity of fatty acid oxidation 
in ischemia (oxygen savings) , activation mechanisms to 
capture and oxidation of glucose for energy production 
pharmacological preconditioning, which includes 
compensatory mechanisms – training through the 
suppression of the synthesis of carnitine, and induction 
of NO biosynthesis, vasoactive effects by reducing 
peripheral vascular resistance and endotelioprotective 
effect via induction of NO biosynthesis. 
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